hospital information

Home  >  Hospital information  >  liver cancer center

We contribute to liver cancer treatment.

Medical department
      /Medical treatment time

Medical contents
Internal medicine, digestive internal medicine, rehabilitation department
Liver disease (hepatitis, liver cirrhosis, liver cancer)
Medical treatment timeMonTueWedThuFriSat
Medical treatment time /Weekday 9:00am - 12:00am / 14:00pm - 17:00pm
/ Saturday 9:00am - 12:00am
Closed day /Sunday, public holidays, 2nd, 4th, 5th Saturday

Medical department/Medical treatment time


Address / 830-0001 Fukuoka Prefecture Kurume City Komorino 2-3-8
TEL / 0942-35-1000

Hospital director greetings

We will not give up on cancer treatment

We specialize in treating patients with various liver diseases using the technology we have cultivated up to now. After graduating from Kurume University School of Medicine in 1986, I belonged to the Angiography Group in 1992, and since then I have been specializing in the treatment of liver cancer. From July 2015, I became inaugural director of Kurume Central Hospital. The goal is to specialize in treating patients with all types of liver disease, to extend the lives of more patients with liver cancer to my treatment and to return them to society. I freely accept many patients with liver cancer in a wide area, and make full use of the technology that I have cultivated up to the treatment of liver cancer for the rest of my life, and I sincerely hope to contribute to society I will. In addition, we will accept the case of difficult advanced liver cancer, which will be introduced from other hospitals, as widely as possible, make treatment plan, and aim to extend the survival time and improve the quality of life. Naturally, patients with general medical and digestive diseases will also receive medical treatment. Thank you.

Kurume central hospital  director Satoshi Itano

Kurume central hospital director:
Itano Satoshi

Advanced hepatocellular carcinoma

Treatment of hepatocellular carcinoma using the special reservoir system indwelling in aorta named “System-I”

We have been engaged in hepatic arterial infusion chemotherapy using subcutaneous implantable hepatic artery reservoir for the treatment of unresectable advanced hepatocellular carcinoma. The objective of hepatic arterial infusion chemotherapy with reservoir is to reduce or eliminate hepatocellular carcinoma by repeated intra-arterial infusion of an anticancer agent into the hepatic artery nourishing the hepatocellular carcinoma through a catheter indwelled in the body for a certain period. Technical learning for reservoir indwelling is important to establish the hepatic arterial infusion with reservoir as a therapeutic policy against advanced hepatocellular carcinoma.

Hepatic arterial infusion chemotherapy using hepatic artery reservoir against advanced hepatocellular carcinoma

low dose fp therapy

low dose fp

The low-dose FP therapy (LFP) is a representative regimen of hepatic arterial infusion chemotherapy against unresectable hepatocellular carcinoma and shows a high response rate but requires long-term hospitalization and has an aspect of difficult coverage by the current health insurance. Since Itano Clinic was established in December 2011, the staff members have contrived and performed “modified FP therapy (mFP)” as an arterial infusion regimen capable of achieving a high response rate by outpatient treatment or short-term hospitalization.

Patients with unresectable hepatocellular carcinoma in whom “modified FP” was introduced in the period from Sep 2011 to Mar 2014 (30 patients)


Originally, System-I was developed for the purpose of implementing TACE repeatedly and dividedly against huge liver carcinoma.But, since 2010, the frequency of encountering a huge liver carcinoma exceeding 10 cm in maximum diameter has decreased extremely. The treatment of advanced hepatocellular carcinoma performed most frequently at present using System-I is IVR therapy performed repeatedly and dividedly by combining multiple regimens depending on diverse tumor status .


In the period from Aug 2008 to Feb 2012, the treatment with System-I using new FP+mFP was performed repeatedly and dividedly against HCC of Stage III-IV in 112 patients.
Response rate: 74/112 (66.1%) MST: 21.5 M.

― Characteristics and merits of System-I ―

(1) Since no hemostatic procedures are necessary, it is possible to perform IVR therapy on the outpatient basis.

(2) It is possible to continue periodic IVR therapy repeatedly and dividedly.

(3) It is possible to select the site of TACE・hepatic arterial infusion on each occasion.

The blood vessel shape of substituted-type hepatic artery, etc. is not influential.

Arterial infusion is possible even at damaged or narrowed arteries.

Applicable also to collateral circulation

(4) Capable of performing IVR therapy also against lesions other than liver lesions